Funding, M&A, exec moves and hiring — every signal, the moment it breaks.See plans →
Vedanta Biosciences secures $60 million in funding, led by AMR Action Fund, to support its pivotal Phase 3 data for VE303.
PRIVATEAug 06, 2026•1 day ago
Amount Raised
$60 Million
Round Type
Venture - Series Unknown
CambridgeHealthcareInvestors
Amr Action Fund
Description
Vedanta Biosciences, a late clinical-stage biopharmaceutical company, has secured $60 million in funding. This financing includes a $40 million round led by existing investors such as AMR Action Fund. The funds will support the Phase 3 RESTORATiVE303 study of VE303 for preventing recurrent C. difficile infections
Related People
Suggested for you
4 contactsVerified contactsMark M., Executive Officer hidden hidden hidden
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech
Watching VEDANTA BIOSCIENCES, INC.? See every signal — funding, hires, M&A, contracts, sentiment.
Book a demoChoose your plan